Clinical Research Directory
Browse clinical research sites, groups, and studies.
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
Sponsor: Fudan University
Summary
To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.
Official title: A Prospective, Non-interventional Study of Different First-line Immunotherapy in Advanced Hepatocellular Carcinoma Patients: Efficacy and Immune Microenvironment Dynamics
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2025-09-01
Completion Date
2028-09-01
Last Updated
2025-08-28
Healthy Volunteers
No
Conditions
Interventions
Sintilimab
Sintilimab will be administered by IV, 200 mg every 3 weeks
Bevacizumab Biosimilar
Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.
Camrelizumab
Camrelizumab will be administered by IV, 200 mg every 2 weeks.
Rivoceranib
Rivoceranib will be administered by oral 250 mg once daily.
Nivolumab
Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks
Ipilimumab
Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.
Locations (1)
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China